The firm said on Wednesday that it has been hiring key sales and marketing personnel as it prepares to ramp up sales in 2025 of its PreTRM proteomic test.
The firm reported that its adjusted diagnostics revenues rose less than 1 percent, excluding the COVID-19 rapid antigen testing business that the firm exited last year.
The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.
The firm reported that its adjusted diagnostics revenues rose less than 1 percent, excluding the COVID-19 rapid antigen testing business that the firm exited last year.